絞り込み

16555

広告

職員以外も加算 ケアマネなど、処遇改善 (毎日新聞)

厚生労働省は15日、来年10月の消費増税に合わせた介護職員の処遇改善策について、介護報酬の加算分を介護職員以外の職種の給与増に使うことを認める方針を示した。対象...

  1. 温暖化でビール高値に 大麦の収穫減で -...
  2. 温暖化でビール高値に - 徳島新聞
  3. 温暖化でビール高値に (デイリースポーツ...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.

著者 Ageno W
Intern Emerg Med.2017 Aug 14 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (113view , 0users)

Full Text Sources

Miscellaneous

Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5-7%. On June 23rd 2017, it became the first direct oral anticoagulant to receive Food and Drug Administration approval for the prevention of venous thromboembolism in acutely ill medical patients, and the first anticoagulant agent to be approved for extended-duration thromboprophylaxis after hospital discharge in this setting. Approval followed the results of the APEX trial, a phase III clinical trial comparing betrixaban (80 mg) administered for 35-42 days with enoxaparin (40 mg) administered for 10 ± 4 days. This study for the first time applied a risk assessment model, integrating clinical factors and a laboratory marker to identify high risk patients. To improve safety, a dose reduction was used for patients with creatinine clearance between 15 and 30 mL/min (betrixaban 40 mg and enoxaparin 20 mg) and for patients receiving concomitant treatment with potent P-glycoprotein inhibitors (betrixaban 40 mg). The primary prespecified analysis tested the hypothesis that the benefit of extended thromboprophylaxis with betrixaban was greatest in patients with elevated D-dimer, but the 21% relative risk reduction failed to meet the prespecified threshold for statistical significance. However, the analysis of the overall study population showed a favorable net clinical benefit with betrixaban, with a statistically significant reduction in all efficacy outcomes and no increase in major bleeding rates. An ongoing trial, MARINER, is also assessing a combined approach for risk stratification comparing extended-duration rivaroxaban with standard duration low molecular weight heparin.
PMID: 28808888 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード